- Home
- AKBA vs KTF Comparison
AKBA vs KTF Comparison
Compare AKBA & KTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- KTF
- Stock Information
- Founded
- AKBA 2007
- KTF 1988
- Country
- AKBA United States
- KTF United States
- Employees
- AKBA N/A
- KTF N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- KTF Finance Companies
- Sector
- AKBA Health Care
- KTF Finance
- Exchange
- AKBA Nasdaq
- KTF Nasdaq
- Market Cap
- AKBA 336.2M
- KTF 384.3M
- IPO Year
- AKBA 2014
- KTF N/A
- Fundamental
- Price
- AKBA $1.83
- KTF $9.47
- Analyst Decision
- AKBA Strong Buy
- KTF
- Analyst Count
- AKBA 1
- KTF 0
- Target Price
- AKBA $7.50
- KTF N/A
- AVG Volume (30 Days)
- AKBA 2.4M
- KTF 103.3K
- Earning Date
- AKBA 11-07-2024
- KTF 01-01-0001
- Dividend Yield
- AKBA N/A
- KTF 3.54%
- EPS Growth
- AKBA N/A
- KTF N/A
- EPS
- AKBA N/A
- KTF 0.39
- Revenue
- AKBA $169,879,000.00
- KTF N/A
- Revenue This Year
- AKBA N/A
- KTF N/A
- Revenue Next Year
- AKBA $30.85
- KTF N/A
- P/E Ratio
- AKBA N/A
- KTF $23.10
- Revenue Growth
- AKBA N/A
- KTF N/A
- 52 Week Low
- AKBA $0.80
- KTF $7.40
- 52 Week High
- AKBA $2.48
- KTF $9.12
- Technical
- Relative Strength Index (RSI)
- AKBA 46.55
- KTF 21.65
- Support Level
- AKBA $1.74
- KTF $9.95
- Resistance Level
- AKBA $1.90
- KTF $10.10
- Average True Range (ATR)
- AKBA 0.09
- KTF 0.09
- MACD
- AKBA -0.03
- KTF -0.06
- Stochastic Oscillator
- AKBA 20.93
- KTF 12.50
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About KTF DWS Municipal Income Trust
DWS Municipal Income Trust is a closed-end, diversified investment management company. The investment objective is to provide high current income exempt from federal income tax by investing in a diversified portfolio of investment-grade tax-exempt securities. Its products include ETFs, Mutual Funds, Closed-End-Funds, Money Market Funds, and others.